Elsevier

Contraception

Volume 75, Issue 5, May 2007, Pages 344-354
Contraception

Original research article
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation

https://doi.org/10.1016/j.contraception.2006.12.019Get rights and content

Abstract

Objectives

The study was conducted to compare risks of adverse cardiovascular and other events associated with the use of drospirenone (DRSP)-containing oral contraceptives (OCs) and other OCs.

Methods and Materials

The European Active Surveillance study (EURAS) was a multinational, prospective, noninterventional cohort study of new users of DRSP, levonorgestrel (LNG) and other progestin-containing OCs. Semiannual follow-up was based on mailed questionnaires, with additional follow-up procedures when needed.

Results

Overall, 58,674 women were followed for 142,475 women-years of observation. Loss to follow-up was 2.4%. Serious adverse and fatal events were rare, and rate ratios were close to unity (1.0). Cox regression analysis of cardiovascular outcomes yielded hazard ratios for DRSP-containing vs. LNG-containing and other OCs of 1.0 and 0.8 (upper 95% confidence limits, 1.8 and 1.3) for venous, and 0.3 and 0.3 (upper 95% confidence limits, 1.2 and 1.5) for arterial thromboembolism, respectively.

Conclusions

Risks of adverse cardiovascular and other serious events in users of a DRSP-containing OC are similar to those associated with the use of other OCs.

Introduction

Oral contraceptives (OCs) are a very popular and efficacious form of reversible birth control. The pill's efficacy plus its convenience gives women both autonomy and flexibility in family planning. This played no small role in the major social movements of the 1960s and 1970s.

The first OCs introduced in the early 1960s contained high doses of both estrogen and progestin. The estrogen doses [150 μg mestranol and 50 μg ethinylestradiol (EE), respectively] were found to be associated with an elevated incidence of cardiovascular side effects, especially venous thromboembolism (VTE).

During the following decades, the estrogen as well as progestin doses were considerably reduced. The scientific discussion on VTE shifted to the type of progestin in the mid-1990s. Epidemiological studies [1], [2], [3], [4] appeared to indicate that OCs containing gestodene and desogestrel had a higher risk of VTE than OCs with levonorgestrel (LNG) and the same amount of EE. In subsequent years, a number of studies have been published with conflicting results. Whether the VTE risk associated with gestodene and desogestrel is real or the result of bias and confounding has been the subject of heated scientific debate. This debate, which has yet to be conclusively resolved [5], [6], is due to the fact that robust safety data that could either substantiate or refute a higher risk of VTE were not available at the time of the “pill scare.”

In order to avoid a comparable situation for the market introduction of an OC with a novel progestin [30 μg EE and 3 mg drospirenone (DRSP)] [7], [8], [9], [10], [11], the manufacturer of this OC commissioned the Center for Epidemiology and Health Research in Berlin to perform a large, prospective, controlled cohort study as part of a phase IV commitment. The safety of this DRSP-containing preparation was assessed using active surveillance of the study participants under the supervision of an independent Advisory Council, which was formed in late 1999.

The methodology and logistics of the study were designed to ensure that within a few years, the risks of short- and long-term use of DRSP-containing OCs and established OCs could be characterized and compared in a study population that was representative of the users of the individual preparations. The main clinical outcomes of interest were cardiovascular events, i.e., incidence rates of arrhythmias, myocardial infarction, stroke, VTE and sudden death.

This publication presents the main safety outcomes of this European Active Surveillance (EURAS) study. Other results of the EURAS study (e.g., return to fertility and pearl index data) will be reported separately.

Section snippets

Materials and methods

A large cohort of women starting OC treatment (first-ever users or switchers to a new product) was actively monitored for the occurrence of rare or unexpected adverse outcomes possibly related to exposure to OCs. The primary focus of the active study monitoring was to assess the occurrence of new cardiovascular events. These events were monitored continuously for the duration of the study. In addition, all other serious adverse events (SAEs; i.e., adverse events that result in death, a

Results

The study was initiated in November 2000 and recruitment was completed in June 2004. The follow-up of study outcomes was terminated in December 2005. The study was conducted in seven European countries where DRSP-containing OCs are marketed: Austria, Belgium, Denmark, France, Germany, the Netherlands and the United Kingdom. A total of 59,510 women (see Table 1) were enrolled by 1113 study centers. Overall, 836 (1.4%) of these 59,510 women had to be excluded because (1) they refused to sign the

Discussion

As a class, estrogen/progestin combinations — OCs as well as hormone replacement preparations — increase the risk of VTE [13]. This heightened risk has been associated with both estrogens and progestins [1], [2], [3], [4]. Given the serious clinical impacts that VTEs can have, the question of whether a newly introduced progestin is associated with a higher risk of VTE is by no means academic. But the heated scientific debate over whether OCs containing gestodene and desogestrel are associated

Conclusions

The independent Advisory Council came to the following conclusions: (1) no major differences among the cohorts were found in the rates for overall SAEs, organ-system specific SAEs, overall mortality and outcome-specific mortality, overall cancer and organ system-specific cancer. (2) Overall, for all outcomes studied, an increased risk for users of a DRSP-containing OC compared to users of other OCs (including LNG-containing OCs) was not identified. These results suggest that the risks of

Acknowledgments

The study was funded by an unrestricted grant from Schering AG. The authors would like express their appreciation to the members of the independent Advisory Council for their constructive criticism and unfailingly fair scientific discussion. The Advisory Council had the following members: Prof. Walter Spitzer (chairman), Canada; Ms. Midori Ashida, Japan (till 2002); Dr. Siham Benchekroun, Morocco (since 2002); Prof. Serge Carriere, Canada; Dr. Jean Cohen, France; Prof. Joe Goldzieher, USA (till

References (32)

  • W.O. Spitzer et al.

    Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women

    BMJ

    (1996)
  • J.M. Kemmeren et al.

    Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

    BMJ

    (2001)
  • A. Rübig

    Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties

    Climacteric

    (2003)
  • R. Schürmann et al.

    Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regime

    Climacteric

    (2004)
  • L. Warming et al.

    Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis

    Climacteric

    (2004)
  • L.A. Heinemann et al.

    Safety of a new oral contraceptive containing drospirenone

    Drug Saf

    (2004)
  • Cited by (388)

    • The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients

      2024, European Journal of Obstetrics and Gynecology and Reproductive Biology
    • Directive clinique n° 444: Hirsutisme: Évaluation et traitement

      2023, Journal of Obstetrics and Gynaecology Canada
    • Guideline No. 444: Hirsutism: Evaluation and Treatment

      2023, Journal of Obstetrics and Gynaecology Canada
    • Human male and female phenotypes depend on lifestyle (smoking and hormonal contraceptives): Implications for prevention and care

      2023, Principles of Gender-Specific Medicine: Sex and Gender-Specific Biology in the Postgenomic Era
    View all citing articles on Scopus
    View full text